Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia (Q39737827)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia |
scientific article |
Statements
1 reference
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia (English)
1 reference
1 reference
Perttu Koskenvesa
1 reference
Tobias Gedde-Dahl
1 reference
Bengt Simonsson
1 reference
Berit Markevärn
1 reference
Kari Remes
1 reference
Jesper Stentoft
1 reference
Anders Almqvist
1 reference
Mats Björeman
1 reference
Max Flogegård
1 reference
Anders Lindblom
1 reference
Claes Malm
1 reference
Kristina Myhr-Eriksson
1 reference
Lotta Ohm
1 reference
Anu Räsänen
1 reference
Marjatta Sinisalo
1 reference
Anders Själander
1 reference
Ulla Strömberg
1 reference
Ole Weiss Bjerrum
1 reference
Franz Gruber
1 reference
Veli Kairisto
1 reference
Karin Olsson
1 reference
Fredrik Sandin
1 reference
Arnon Nagler
1 reference
Johan Lanng Nielsen
1 reference
Henrik Hjorth-Hansen
1 reference
Nordic CML Study Group
1 reference
17 June 2011
1 reference
Identifiers
1 reference